IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, C

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. INTC
2. SPCX
3. DSX
4. GNK
5. AWK
6. MDA
7. ACN
8. NTMFF
9. III
10. SAN

Go back to IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, C
(NASDAQ: IDYA) Delayed: 31.23 --0 (-0%)
Previous Close $31.23    52 Week High $ 
Open $31.23    52 Week Low $ 
Day High $31.23    P/E N/A 
Day Low $31.23    EPS $ 
Volume 1,106